65th ASH Annual Meeting & Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Fundamental Science, Translational Research, Diseases

Harbor Ballroom (Manchester Grand Hyatt San Diego)

Moderators:

Kenneth H. Shain, MD, PhD, Moffitt Cancer Center and Martin F. Kaiser, MD, FRCP, FRCPath, The Institute of Cancer Research

Disclosures:

Shain: Amgen: Honoraria; Karyopharm Therapeutics: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria; Adaptive Biotechnologies: Honoraria; Abbvie: Honoraria, Research Funding; Takeda Oncology: Honoraria; Janssen: Honoraria, Research Funding; Sanofi Oncology: Honoraria. Kaiser: GSK: Consultancy; Celgene/BMS: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Regeneron: Consultancy; Takeda: Honoraria; Seagen: Consultancy; Karyopharm: Consultancy; Pfizer: Consultancy.

These abstract examine basic molecular feature associated with MM and premalignant conditions.

4:30 PM

637

Multiple Myeloma with 1q Gain/Amplification Shows Reduced CD38 Expression Via IL-6R Overexpression

Wataru Kuroki, MD¹^*, Akihiro Kitadate, M.D., Ph.D.², Masahiro Yamada²^*, Sayaka Iwama³^*, Yuto Takahashi, M.S.⁴^*, Yuki Fujioka²^*, Takahiro Kobayashi, M.D., Ph.D.²^*, Sho Ikeda, M.D., Ph.D.², Kentaro Narita⁵^*, Kosei Matsue⁵ and Naoto Takahashi, M.D., Ph.D.²

¹Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, AKI, Japan
²Department of Hematology, Nephrology and Rheumatology, Akita University, Akita, Japan
³Department of Life Science, Akita University, Akita, Japan
⁴Department of Integrated Engineering Science, Akita University, Akita, Japan
⁵Division of Hematology/Oncology, Kameda Medical Center, Chiba, Japan

4:45 PM

638

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, MD¹, Marcella Kaddoura, MD², Alexandra Maria Poos, PhD³^*, Anthony Cirrincione, PhD⁴^*, Benjamin Diamond, MD⁴, Kylee H Maclachlan, MBChB, PhD⁵, Bachisio Ziccheddu⁶^*, Elias K. Mai, M.D.⁷^*, Hartmut Goldschmidt⁸, Katja Weisel, MD⁹, Roland Fenk, MD, PhD¹⁰^*, Gareth J. Morgan, M.D., Ph.D.¹¹^*, Saad Z Usmani, MD¹², Ola Landgren, MD⁶, Marc S. Raab³^* and Niels Weinhold, PhD⁷^*

¹Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, PALMETTO BAY, FL
²Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Dearborn, MI
³Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁴Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
⁵Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
⁷Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁸University Clinic Heidelberg, Heidelberg, Germany
⁹University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
¹⁰Department of Hematology, Oncology and Clinical Immunology,, University Hospital Düsseldorf, Duesseldorf, Germany
¹¹Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
¹²Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

5:00 PM

639

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, MD¹^*, Marilena Tauro, PhD²^*, Bachisio Ziccheddu³^*, Alexandra Maria Poos, PhD⁴^*, Abdessamad Youssfi Alaoui, PhD¹^*, Mark B Meads, PhD⁵^*, Kylee H Maclachlan, MBChB, PhD⁶, Saad Z Usmani, MD⁷, Marc S. Raab⁸^*, Gareth J. Morgan, M.D., Ph.D.⁹^*, Niels Weinhold, PhD⁸^*, Kenneth H. Shain, MD, PhD², Ola Landgren, MD³ and Francesco Maura, MD¹⁰

¹Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
²H. Lee Moffitt Cancer Center, Tampa, FL
³Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL
⁴Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁶Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
⁹Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
¹⁰Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, PALMETTO BAY, FL

5:15 PM

640

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, MD¹, Anil Aktas-Samur, PhD²^*, Domenico Maisano, PhD, MSc³^*, Claire Gao, B.Sc⁴^*, Na Liu, M.Sc⁴^*, Vanessa Favasuli, PhD⁵^*, Marcello Turi, PhD⁶^*, Pietro Folino, M.Sc⁷^*, Mariateresa Fulciniti, PhD⁸, Annamaria Gulla, MD^8,9, Kenneth C. Anderson, MD¹⁰, Mehmet K. Samur, PhD¹¹^* and Nikhil C Munshi, MD¹⁰^*

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA
³Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Medical Oncology, Dana Farber Cancer Institute, Harvard medical School, Boston, MA
⁶Candiolo Cancer Institute FPO-IRCCS, Candiolo, ITA
⁷Dana Farber Cancer Institute, Boston, MA
⁸Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy
¹⁰Dana-Farber Cancer Institute, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Boston, MA
¹¹Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA

5:30 PM

641

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Enze Liu, PhD¹^*, Nathan Becker, MS¹^*, Parvathi Sudha¹^*, Aneta Mikulasova, PhD²^*, Mohammad Abu Zaid, MBBS¹, Attaya Suvannasankha, MD¹, Kelvin P. Lee, MD¹, Rafat Abonour, MD¹ and Brian A. Walker, PhD^1,3

¹Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN
²Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
³Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN

5:45 PM

642

Multiple Myeloma B Cells and Pre-Plasma Cells Are Important Reservoirs for Myeloma Relapse Following Plasma Cell-Directed Therapy and Prevent Cure with Standard Therapies

Rodger E. Tiedemann^1,2, Ines Tagoug, PhD³^*, Natalie Erdmann, MSc³^*, Ali Mahdipour-Shirayeh, PhD⁴^* and Kim Chan Chung, PhD^3,5^*

¹School of Medical Sciences, Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
²Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
³Princess Margaret Cancer Centre, Toronto, ON, Canada
⁴Princess Margaret Cancer Centre, Toronto, ON, CAN
⁵Amgen, Toronto, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States